Xbiotech Inc (NASDAQ:XBIT) recorded a decrease of 5.26% in shares shorted. In January was announced XBIT’s total 1.65 million shares shorted by FINRA. That’s 5.26% down from 1.74 million shares. 71 days will cost XBIT with 23,200 average volume to restore its former position. Xbiotech Inc’s shares shorted float is 8.38%.
The stock increased 2.87% or $0.17 during the last trading session, reaching $6.1.Currently XBiotech Inc. is downtrending after 7.38% change in last January 19, 2018. XBIT has 77,021 shares volume. The stock underperformed the S&P 500 by 7.38%.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.The company has $218.50 million market cap. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.Currently it has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
For more XBiotech Inc. (NASDAQ:XBIT) news released briefly go to: Globenewswire.com, Benzinga.com, Globenewswire.com, Bizjournals.com or Nasdaq.com. The titles are as follows: “XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology – GlobeNewswire” released on April 16, 2018, “The Daily Biotech Pulse: Foamix (NASDAQ:FOMX) Jumps on Data, Positive Results for Galapagos (NASDAQ:GLPG)-Gilead (NASDAQ:GILD)’s Rheumatoid Arthritis Drug, Bausch Health (NYSE:BHC) Trims Debt – Benzinga” on September 12, 2018, “XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus – GlobeNewswire” with a publish date: January 25, 2018, “European regulators raise questions about Austin drugmaker’s lead cancer treatment – Austin Business Journal” and the last “UBX To Report Phase I Data In Q1, NVTA On Watch, NTGN Faces Busy Year Ahead – Nasdaq” with publication date: October 23, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.